

Pfizer Registry of Outcomes in Growth Hormone RESearch (PROGRES) 2.0: A multi-country non-interventional, observational, retrospective cohort study among participants treated with human growth hormone (hGH) treatments Genotropin (somatropin) and Ngenla (somatrogon) under routine clinical care.

First published: 01/10/2025

Last updated: 20/02/2026

Study

Ongoing

Administrative details

EU PAS number

EUPAS1000000705




















Study ID

1000000705

DARWIN EU® study

No

Study countries

-  Armenia
 -  Belgium
 -  Brazil
 -  Bulgaria
 -  China
 -  Czechia
 -  France
 -  Georgia
 -  Germany
 -  Hong Kong
 -  Italy
 -  Malaysia
 -  Poland
 -  Portugal
 -  Saudi Arabia
 -  Slovenia
 -  Sri Lanka
 -  United Kingdom
 -  United States
-

Study description

PROGRES 2.0 is a multi-country, non-interventional, observational cohort study conducted voluntarily by Pfizer to assess the long-term effectiveness and safety of both a daily hGH Genotropin (somatropin) and a long-acting hGH Ngenla (somatrogon), at the discretion of the treating physician according to routine clinical care in a real-

world setting.

This study will gather the data as a sub-study of the Global Registry for Novel Therapies in

Rare Bone and Endocrine Conditions (GloBE-Reg). Participants can be located anywhere in the world and will be followed for up to 10 years.

Study status

Ongoing

Contact details

Study institution contact

Lissette Cespedes lissette.cespedes@pfizer.com

Study contact

lissette.cespedes@pfizer.com

Primary lead investigator

Lissette Cespedes

Primary lead investigator

Study timelines

Date when funding contract was signed

Planned: 21/05/2025

Actual: 21/05/2025

Study start date

Planned: 30/09/2025

Actual: 03/10/2025

Date of final study report

Planned: 28/02/2036

Study protocol

[NIS Protocol PROGRES 2.0_19Sep2025.pdf](#) (12.21 MB)

[C0311028_NIS Protocol PROGRES 2.0_V2.0_30JAN2026.pdf](#) (1.86 MB)

Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable

Methodological aspects

Study type

Study type list

Study topic:

Disease /health condition

Human medicinal product

Study type:

Non-interventional study

Scope of the study:

Effectiveness study (incl. comparative)

Safety study (incl. comparative)

Study Design

Non-interventional study design

Cohort

Study drug and medical condition

Medicinal product name

GENOTROPIN

[NGENLA](#)

Study drug International non-proprietary name (INN) or common name

SOMATROPIN

SOMATROGON

Anatomical Therapeutic Chemical (ATC) code

(H01AC01) somatropin

somatropin

(H01AC08) somatrogon

somatrogon

Data management

ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

Use of a Common Data Model (CDM)

CDM mapping

No

Data quality specifications

Check conformance

No

Check completeness

No

Check stability

No

Check logical consistency

No

Data characterisation

Data characterisation conducted

No